UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

November 30, 2027

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

UCAR T-cell group

A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells

Trial Locations (1)

RECRUITING

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors

collaborator

Shanghai Xiniao Biotech Co., Ltd.

INDUSTRY

lead

Zhejiang University

OTHER

NCT06920433 - UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter